SpringWorks/SWTX

$50.51

4.18%
-
1D1W1MYTD1YMAX

About SpringWorks

SpringWorks Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on acquiring, developing and commercializing life-changing medicines for patients living with severe rare diseases and cancer. It has a differentiated targeted oncology pipeline spanning solid tumors and hematological cancers, including two late-stage clinical trials in rare tumor types as well as several programs addressing highly prevalent, genetically defined cancers. Its product candidate, nirogacestat, is an oral, small molecule gamma secretase inhibitor (GSI), in development as a monotherapy for the treatment of desmoid tumors, a rare and often debilitating and disfiguring soft tissue tumor. Its second product candidate is mirdametinib, an oral, small molecule MEK inhibitor in development for the treatment of neurofibromatosis type 1-associated plexiform neurofibromas (NF1-PN), a rare tumor of the peripheral nerve sheath that causes pain and disfigurement.

Ticker

SWTX

Sector

Healthcare

Trading on

NASDAQ

Industry

Biotechnology & Drugs

CEO

Saqib Islam

Employees

227

Headquarters

Stamford, United States

SpringWorks Metrics

BasicAdvanced
$3.61B
Market cap
-
P/E ratio
-$4.89
EPS
0.83
Beta
-
Dividend rate

What the Analysts think about SpringWorks

Analyst Ratings

Majority rating from 8 analysts.
Buy

Price Targets

Average projection from 7 analysts.
23.96% upside
High $75.00
Low $47.00
$50.51
Current price
$62.61
Average price target

SpringWorks Financial Performance

Income StatementBalance sheetCash Flow

Income Statement

Revenues and expenses
0% profit margin
QuarterlyAnnual
Q3 23
QoQ growth
Revenue
$0
-
Net income
$-79.4M
1.93%
Profit margin
0%
-

SpringWorks Earnings Performance

Earnings per share (EPS)

Company profitability
Beat by 4.51%
QuarterlyAnnual
Q4 22
Q1 23
Q2 23
Q3 23
Q4 23
Actual
-$1.17
-$1.18
-$1.25
-$1.27
-
Expected
-$1.22
-$1.25
-$1.26
-$1.33
-$1.24
Surprise
-4.23%
-5.9%
-0.95%
-4.51%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. Fundamental data, financials and analyst ratings are sourced from Refinitiv.

Upcoming events

Buy or sell SpringWorks stock

Buy or sell SpringWorks stock

Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.
Start investing